These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 498715)

  • 1. Oral melphalan kinetics.
    Alberts DS; Chang SY; Chen HS; Evans TL; Moon TE
    Clin Pharmacol Ther; 1979 Dec; 26(6):737-45. PubMed ID: 498715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of intravenous melphalan.
    Alberts DS; Chang SY; Chen HS; Moon TE; Evans TL; Furner RL; Himmelstein K; Gross JF
    Clin Pharmacol Ther; 1979 Jul; 26(1):73-80. PubMed ID: 445964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of food on oral melphalan absorption.
    Reece PA; Kotasek D; Morris RG; Dale BM; Sage RE
    Cancer Chemother Pharmacol; 1986; 16(2):194-7. PubMed ID: 3948305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.
    Woodhouse KW; Hamilton P; Lennard A; Rawlins MD
    Eur J Clin Pharmacol; 1983; 24(2):283-5. PubMed ID: 6840181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.
    Bosanquet AG; Gilby ED
    Eur J Cancer Clin Oncol; 1982 Apr; 18(4):355-62. PubMed ID: 6889512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease.
    Tattersall MH; Jarman M; Newlands ES; Holyhead L; Milstead RA; Weinberg A
    Eur J Cancer (1965); 1978 May; 14(5):507-13. PubMed ID: 648565
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of high dose melphalan.
    Hersh MR; Ludden TM; Kuhn JG; Knight WA
    Invest New Drugs; 1983; 1(4):331-4. PubMed ID: 6678879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.
    Loos U; Musch E; Engel M; Hartlapp JH; Hügl E; Dengler HJ
    Eur J Clin Pharmacol; 1988; 35(2):187-93. PubMed ID: 3191937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients.
    Alberts DS; Chen HS; Chang SY; Peng YM
    Recent Results Cancer Res; 1980; 74():293-9. PubMed ID: 6160601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
    Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.
    Taha IA; Ahmad RA; Gray H; Roberts CI; Rogers HJ
    Cancer Chemother Pharmacol; 1982; 9(1):57-60. PubMed ID: 7139852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases.
    Ardiet C; Tranchand B; Biron P; Rebattu P; Philip T
    Cancer Chemother Pharmacol; 1986; 16(3):300-5. PubMed ID: 3516430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of cimetidine with oral melphalan. A pharmacokinetic study.
    Sviland L; Robinson A; Proctor SJ; Bateman DN
    Cancer Chemother Pharmacol; 1987; 20(2):173-5. PubMed ID: 3311444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.
    Ehrsson H; Eksborg S; Osterborg A; Mellstedt H; Lindfors A
    Med Oncol Tumor Pharmacother; 1989; 6(2):151-4. PubMed ID: 2747308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of melphalan in children following high-dose intravenous injection.
    Taha IA; Ahmad RA; Rogers DW; Pritchard J; Rogers HJ
    Cancer Chemother Pharmacol; 1983; 10(3):212-6. PubMed ID: 6861266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of high-dose melphalan in children and adults.
    Gouyette A; Hartmann O; Pico JL
    Cancer Chemother Pharmacol; 1986; 16(2):184-9. PubMed ID: 3948304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of L-leucine on oral melphalan kinetics in patients.
    Reece PA; Dale BM; Morris RG; Kotasek D; Gee D; Rogerson S; Sage RE
    Cancer Chemother Pharmacol; 1987; 20(3):256-8. PubMed ID: 3315285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
    Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenytoin: pharmacokinetics and bioavailability.
    Gugler R; Manion CV; Azarnoff DL
    Clin Pharmacol Ther; 1976 Feb; 19(2):135-42. PubMed ID: 1261151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.